Varenicline for smoking cessation: A review of the literature  by Kaur, Kirandeep et al.
CURRENT THERAPEUTIC RESEARCH
VOLUME 70, NUMBER I, FEBRUARY 2009
Varenicline for Smoking Cessation: A Review of the
Literature
Kirandeep Kaur, MD; Sandeep Kaushal, MD; and Sarvesh C. Chopra, MD
Department of Pharmacology, Old Dayanand Medical College and Hospital, Ludhiana,
India
ABSTRACT
BACKGROUND: Smoking is the leading preventable risk to human health. Vari-
ous agents have been used to promote smoking cessation, but none has had long-term
efficacy. Varenicline, a new nicotinic ligand based on the structure of cytosine, was ap-
proved by the US Food amd Drug Administration for use as a smoking cessation aid.
OBJECTIVES: The aims of this review were to provide an overview on the
mechanism of action and preclinical and clinical data of the new drug, varenicline, and
to discuss the current and future impact of varenicline as a treatment for smoking
cessation.
METHODS: MEDLINE, BIOSIS, and Google scholar databases were searched
(March 1, 2007-July 1, 2008) using the terms varenicline, smoking cessation, and nico-
tinic receptors. Full-text articles in English were selected for reference, and articles
presenting the mechanism of action, pharmacokinetics, and data from preclinical and
clinical trials were included.
RESULTS: The initial literature search yielded 70 papers. A total of 20 articles
fulfilled the inclusion criteria. Varenicline, an u4132 nicotinic acetylcholine receptor
partial agonist, inhibits dopaminergic activation produced by smoking and decreases
the craving and withdrawal syndrome that accompanies cessation attempts. In Phase
III clinical trials, the carbon monoxide-confirmed 4-week continuous abstinence rates
were significantly higher with varenicline than with buproprion sustained release or
placebo for weeks 9 through 12. Varenicline has been found to be well tolerated, with
nausea being the most commonly reported (28.1 %) adverse event.
CONCLUSIONS: Varenicline is the first drug for smoking cessation that has been
found to have significant effectiveness in long-term relapse prevention (up to 52 weeks).
Varenicline, with its unique profile of agonist and antagonist properties, increased
cessation rates (both short- and long-term) compared with both placebo and bu-
propion sustained release. (Curr Ther Res Clin Exp. 2009;70:35-54) © 2009 Excerpta
Medica Inc.
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INTRODUCTION
Cigarette smoking remains the leading preventable cause of disease and premature
death in the United States, claiming an estimated 438,000 lives per year. 1 Although
80% of people who smoke cigarettes desire to quit, only 35% attempt to quit, and
only 5% are able to quit smoking without an aid. 2 In the mid-1970s there was no
effective pharmacologic treatment for tobacco dependence, and few behavioral scien-
tists or pharmaceutical companies were making significant efforts in this area. 3 Thirty
years later this situation has changed substantially.
Seven smoking cessation pharmacotherapies are currently approved by the US Food
and Drug Adminstration (FDA). Five of these are nicotine replacement products (gum,
patch, nasal spray, inhaler, and lozenge).4 Each delivers nicotine, the agent that is re-
sponsible for the development of tobacco dependence, so that the nicotine withdrawal
symptoms and the craving for cigarettes are reduced while the patient is quitting smok-
ing. Another approved smoking cessation therapy, bupropion sustained-release (SR),
helps in smoking cessation by inhibiting dopamine reuptake in the central nervous
system.s Bupropion also antagonizes nicotinic acetylcholine receptor function. The pri-
mary mechanism of bupropion's effect on smoking cessation is not clear, but it appears
to be via reduction of withdrawal symptoms by mimicking nicotine effects on dopa-
mine and noradrenaline. 6 I t increases smoking cessation rates compared with both
placeb07 and the nicotine patch.7,8 Varenicline, a partial nicotine agonist, is the latest
addition to the list of drugs approved by the FDA for smoking cessation.9 The chemical
structure of varenicline is (7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino[2,3h][3]
benzazepine[2R,3R]-2,3-dihydroxybutanedioate) (Figure 1).10
The purpose of this review was to provide an overview of the clinical trial data of
varenicline, with a focus on Phase II and III trials and to discuss the current and future
impact of varenicline as a form of smoking cessation therapy.
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Figure 1. Chemical structure of varenicline.10
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METHODS
A search was performed using the MEDLINE, BIOSIS, and Google scholar databases
(March 1, 2007-July 1,2008) for literature using the terms varenicline, smoking cessation,
and nicotinic receptors. Full-text articles in English were selected for reference, and ar-
ticles presenting the mechanism of action, pharmacokinetics, and data from preclini-
cal and clinical trials were included. Reference lists from all retrieved articles were
included in the search.
RESULTS
SEARCH RESULTS
The initial literature search yielded 70 papers. A total of 20 articles fulfilled the
inclusion criteria.
MECHANISM OF ACTION
The dopaminergic neurons located in the midbrain reward center, including the
ventral tegmental area (VTA) and substantia nigra pars compacta, play pivotal roles
in drug reinforcement, motility, and associative motor learning. 11 ,12 An increase in
the release of dopamine from VTA neurons onto their targets in the nucleus accum-
bens contributes to drug reinforcement. 13 ,14
The midbrain dopaminergic system plays a key role in nicotine dependence. 1s
Dopamine antagonists and lesions of dopamine neurons or of the nucleus accumbens
have been found to reduce self-administration in rats. 16 When a sufficient concentration
of nicotine is carried in the blood to activate (u4)3(132)2 receptors in the VTA, a burst
firing of dopamine neurons occurs. The terminals of these neurons are in the medial shell
and core areas of the nucleus accumbens. This stimulation of dopamine neurons causes
increased release of extrasynaptic dopamine in the nucleus accumbensY
Attention has now been focused on the specific inhibitors of (u4)3(132)2 receptors.
Varenicline is an u4132 nicotinic acetycholine receptor partial agonist. It is a synthetic
derivative of a natural plant alkaloid, cytisine. Cytisine has been used in Bulgaria since
the 1960s as a smoking cessation aid. 18 After the development of varenicline, a review
of cytisine was conducted. 19 Cytisine provided a structural starting point for the de-
velopment of the higher-affinity varenicline. The agonist effect of oral varenicline on
dopamine release is 35% to 60% of that observed with nicotine, which is theoretically
sufficient to attenuate craving and withdrawal without producing its own dependence
syndrome.20
Varenicline binds selectively and with high affinity to these receptors, thereby
preventing nicotine from binding to the u4132 receptors (Figure 2).17 In vitro electro-
physiologic studies and in vivo neuron chemical studies have found that varenicline,
acting as a typical partial agonist, binds to the receptors and stimulates receptor-
mediated activity, but at a significantly lower concentration than the full agonist (ie,
nicotine).20-23 The slower release of dopamine with varenicline compared with smok-
ing might also reduce the potential for abuse. 2o ,24 Varenicline also has a competitive
antagonist effect on nicotine due to a substantially higher affinity for the u4132 recep-
tor. 20 Varenicline blocks the ability of nicotine to activate u4132 receptors and thus to
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Figure 2. The effects of (A) nicotine from cigarettes, (B) nicotine withdrawal, and (C) varenicline on nicotinic receptors and dopa-
minergic release. Reprinted with permissionP
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stimulate the central nervous meso limbic dopaminergic system. It inhibits dopamin-
ergic activation and simultaneously provides relief from craving and withdrawal
symptoms that accompany smoking cessation. 2o Varenicline has been found to be a
full agonist at the u 7-homomeric receptors.
23 Several experimental studies have found
that u 7-homomeric nicotinic receptors in the VTA are involved in the acute effect of
nicotine on dopamine release in the nucleus accumbens. 25 ,26 The combination of the
actions on u4132 and u 7 receptors may explain the mechanism of action of varenicline
as a smoking cessation aid.
PHARMACOKINETICS
The pharmacokinetics of varenicline have been studied in various preclinical and
Phase I trials. 2o ,27 The metabolism and disposition of varenicline was examined in
rats, mice, monkeys, and humans after oral administration. 27 The majority of vareni-
cline was unchanged in the circulation of all these species, and metabolites were
primarily excreted in the urine. A large percentage of varenicline was excreted as un-
changed parent drug (84%,90%,75%, and 81% of the dose in rats, mice, monkeys,
and humans, respectively). Metabolites observed in excreta arose via N-carbamoyl
glucuronidation and oxidation. These metabolites were also observed in the circula-
tion, in addition to metabolites that arose via N-formylation and formation of a
novel hexose conjugate. Metabolites observed in humans were also observed in other
animal species, and there was no readily observable difference between smokers and
nonsmokers. 27
In a Phase I, double-blind, placebo-controlled, single-dose, dose-escalation study,
the clinical pharmacology of single doses of varenicline in healthy smokers and non-
smokers under fed and fasted conditions was determined. The subjects were adminis-
tered oral doses of varenicline ranging from 1 to 10 mg. All subjects had quantifiable
plasma concentrations of varenicline up to 120 hours postdose. 28 Over this dose range,
T max occurred at 1.50 to 4.25 hours after administration and the mean t 1/2 of the decay
phase ranged from 14.4 to 19.5 hours. Dose-proportional increases were observed in
Cmax and AUCo_oo from 0.1 to 3 mg only; at higher doses there was no further increase
in Cmax or AUCo_oo ' All 4 subjects given the 10-mg dose vomited shortly after dosing,
which may have affected Cmax and AUCo_oo estimates. Smoking restriction produced
no detectable change in the pharmacokinetic profile of varenicline. 28
In another double-blind, placebo-controlled, multiple-dose, dose-escalation study
of the pharmacokinetics of varenicline in healthy subjects who smoked, 4 dose levels
were studied (1, 2, and 3 mg QD, and 1 mg BID).29 The T max of varenicline was
achieved at 2 to 4 hours after administration for each regimen after both single and
multiple doses of varenicline. Plasma varenicline concentrations were detectable
from 96 to 144 hours after QD dosing with 1 and 2 mg and up to 144 hours after
3 mg QD and 1 mg BID. The individual t 1/2values ranged from 16 to 27 hours after
a single administration and from 18 to 43 hours after repeat administrations. Steady-
state conditions were reached by day 4. The overall mean (SD) accumulation factor
after once-daily dosing with 1,2, and 3 mg was 1.94 (0.31) and after BID dosing it
was 2.85 (0.73). The pharmacokinetics of varenicline were not time- or concentration-
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dependent upon repeat dosing. There was an apparent decrease (~50%-90%) in both
mean plasma nicotine and conitine concentrations compared with baseline after ad-
ministration of the 2- and 3-mg QD doses and the 1-mg BID dose of varenicline.
Similar decreases (~60%-80%) in the mean number of cigarettes smoked per day
were observed with the 2- and 3-mg QD doses. The study did not show any change
in renal elimination with the QD or BID regimen. Estimates of renal clearance were
similar across treatments and study days, indicating that varenicline elimination was
not altered with repeat dosing.
After oral administration of varenicline, absorption is complete and systemic bio-
availability is high. 27 Bioavailability of oral varenicline is unaffected by food or by the
time of administration. 28 The elimination t1/2 of varenicline is ~24 hours. 21 Tmax is
reached in 3 to 4 hours after oral administration. Over the recommended dose range,
varenicline exhibits linear pharmacokinetics after single or repeated doses. 28 Vareni-
cline is not highly protein bound (20%) in plasma. Varenicline is almost exclusively
excreted by the kidneys in humans. 21 It is not known whether varenicline is excreted
in breast milk (Table 1).
The pharmacokinetics of varenicline are unaffected in patients with hepatic insuf-
ficiency; however, patients with impaired renal function may be at an increased risk
of toxic reactions as the drug is excreted exclusively by the kidneys.3o The manufac-
turer of the drug has instructed that the patients with severe renal impairment should
receive a reduced initial dose. 10
In a double-blind, placebo-controlled, parallel-group study, the single- and multiple-
dose pharmacokinetics and tolerability of varenicline were observed in elderly smok-
ers. 31 Twenty-four healthy male and female volunteers aged >65 years who had
smoked ::0-10 cigarettes per day for ::0-1 year were enrolled. Two groups, each consisting
of 12 eligible volunteers, were randomized in a 2: 1 ratio to receive varenicline or pla-
cebo: in group 1, varenicline 1 mg QD was administered for 7 days, and in group 2,
varenicline 1 mg BID on days 1 through 6 and a single dose on day 7 was adminis-
tered. Varenicline plasma concentrations were higher on day 7 than after a single ad-
ministration, indicating accumulation of varenicline upon repeat dosing. Maximum
plasma concentrations were achieved within 2 to 3 hours following single or repeat
Table I. Pharmacokinetics of varenicline.27- 29
Bioavailability
Plasma protein binding
Tmax
Time to Css
Metabolism
Active metabolites
Elimination
Elimination t1/ 2
ess = steady-state concentration.
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High, unaffected by food or time of administration
<20%
3-4 hours
4 days
Minimal hepatic metabolism
N-formyl conjugate, N-carbamoyl glucoronide,
N-hexose conjugate, and an unidentified metabolite
Renal, 92% unchanged
~24 hours
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oral administration with each dose regimen. Steady state conditions developed within
4 days of repeated administration. The steady state minimum plasma concentrations
pooled from days 4 to 8 averaged ~3.3 ng/mL after 1 mg QD and 6.0 ng/mL after
1 mg BID dosing. Adverse events were reported by 4 participants (50%) receiving
varenicline 1 mg QD, 3 (38%) receiving BID treatment, and 5 (62%) in the placebo
group. The most commonly reported adverse event was nausea: 2 in group 1, 1 in
group 2, and 1 in the placebo group. There was no evidence of concentration- or time-
dependent changes in varenicline pharmacokinetics following repeated once or twice
daily administration for 7 consecutive days. According to the authors, no dose adjust-
ment is necessary based on age alone. 31 The drug is not recommended for patients
aged < 18 years, as no studies have been conducted in this age group. 10
DOSE
The recommended dose of varenicline is 1 mg BID after a i-week titration period
(starting with 0.5 mg QD, then 0.5 mg BID, and then 1 mg BID). The initial dose
titration reduced the incidence of nausea. 32 ,33 Varenicline should be started 7 days
before the date identified for smoking cessation.
DRUG INTERACTIONS
Since varenicline is not a substrate for the cytochrome P450 family of metabolizing
enzymes, it is expected to interact with few drugs. 29 The safety of the combination of
bupropion and varenicline has not yet been reported, and the safety and efficacy of
varenicline with other smoking cessation therapies are yet to be established. 10 Vareni-
cline was not found to have any clinically significant interactions with digoxin, cimeti-
dine, metformin,30 or warfarin. 34
VARENICLINE CLINICAL TRIAL DATA
The literature search for clinical trials yielded 8 papers.4,3 2,3S-40 Six double-blinded,
randomized, controlled trials evaluated varenicline for smoking cessation. One open-
label randomized trial compared varenicline with nicotine replacement therapy (NRT)
but without a placebo arm. 40 One trial evaluated varenicline as an aid to relapse
prevention37 (Table II).
Clinical Efficacy
A Phase II, randomized, double-blind, placebo- and active-controlled, multicenter,
parallel-group study was conducted to select the optimal dose for larger-scale Phase
III trials and to assess the efficacy and tolerability of 3 different doses of varenicline
administered for 6 weeks.3s Subjects were healthy smokers aged 18 to 65 years. They
were required to have smoked an average of 10 cigarettes per day during the previous
year without abstinence of > 3 months. The primary efficacy measure was the continu-
ous quit rate (CQR) for any 4-week period, which was defined as abstinence for any
28-day period during the treatment phase. The secondary efficacy measures included
the carbon monoxide (CO)-confirmed (<; 10 ppm) 4-week CQR for weeks 4 to 7, as
well as CQRs from week 4 to weeks 12, 24, and 52. Craving was assessed using the
41
Table II. Overview of clinical trials used in this review.
Oncken et al 32 Phase II, randomized, double-
blind, placebo-controlled,
multicenter clinical trial
Trial
Jorenby et al4
Design
Phase III, randomized, double-
blind, placebo-controlled;
consisted of a 12-week
treatment period with follow-up
to week 52
Dose
Varenicline 1 mg BID
(titrated as 0.5 mgjd
for days 1-3, 0.5 mg BID
for days 4-7, then 1 mg
BID through week 12)
Bupropion SR 150 mgjd
for days 1-3, then
150 mg BID through
week 12
Placebo
Varenicline 0.5 mg BID
nontitrated
Varenicline 0.5 mg BID
titrated
Varenicline 1 mg BID
nontitrated
Varenicline 1 mg BID
titrated
Placebo
Subjects
Aged 18-75 years,
smoked ~10 cigarettesjd
during the previous year
without a period of
abstinence >3 months
Aged 18-65 years,
in general good health,
smoked ~10 cigarettesjd
during the previous year
without a period of
abstinence >3 months
Objectives
Primary end point:
exhaled CO-confirmed
4-week CAR for weeks
9-12
Secondary end points:
(1) CAR from weeks
9-24 and from weeks
9-52; (2) 7-day point
prevalence abstinence
rates at weeks 12, 24,
and 52
Primary end point:
exhaled CO-confirmed
CQR for weeks 4-7
and 9-12 during treat-
ment and CARs for
weeks 9-52 for each
dose relative to
placebo
Secondary end points:
during the treatment
period, CO-confirmed
7-day point prevalence
abstinence and
changes in the MNWS
and the mCEQ
(continued)
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Table II (continued).
Trial Design Dose Subjects Objectives
Phase II, randomized, double- Varenicline 0.3 mgjd
blind, parallel-group, multicenter, Varenicline 1.0 mgjd
placebo- and active-controlled Varenicline 1.0 mg BID
clinical trial Bupropion SR 150 mg BID
Placebo
52-Week, randomized, open-label
(first 12 weeks) and then
double-blind treatment phase
(next 12 weeks) and then
nontreatment follow-up phase
for 28 weeks.
Those who successfully
abstained from smoking, use
of tobacco, NRT for '27 days
of the treatment period
were randomly assigned to
varenicline 1 mg BID
or placebo.
Aged 18-75 years,
smoked '210 cigarettesjd,
had <3 months of
smoking abstinence in
the past year,
motivated to quit
Nides et al35
Gonzales et al36
Tonstad et al37
Phase III, randomized, double- Varenicline 1 mg BID
blind, parallel-group, multicenter, (titrated as 0.5 mgjd
placebo- and active-treatment for days 1-3,
controlled trial with a 12-week 0.5 mg BID for
treatment phase and blinded days 4-7, 1 mg BID
poststudy drug follow-up to through week 12)
week 52 Bupropion SR 150 mgjd
for days 1-3, then
150 mg BID through
week 12
Placebo
Varenicline 1 mg BID with
an initial dose titration
for 12 weeks
Aged 18-65 years, Primary end point:
in general good health, exhaled CO-confirmed
smoked an average of CQR for any 4 weeks
10 cigarettesjd during Secondary end points:
the previous year without CQRs from weeks 4-7
a period of abstinence and weeks 4-12, 24,
>3 months and 52
Aged 18-75 years, Primary end point:
smoked '210 ciga rettesjd, exhaled CO-confirmed
had <3 months of 4-week CAR for
smoking abstinence weeks 9-12
in the past year Secondary end points:
(1) CARs from
weeks 9-24 and from
weeks 9-52; (2) 7-day
point prevalence
abstinence rates at
weeks 12, 24, and 52
Primary end point:
exhaled CO-confirmed
4-week CAR for
weeks 13-24
Secondary end points:
(1) CAR from
weeks 13-52; (2) 7-day
point prevalence
abstinence rates at
weeks 12, 24, and 52
(continued)
Nakamura et al39 Randomized, double-blind,
placebo-controlled,
multicenter clinical trial
Table II (continued).
Trial
Tsai et al38
Design
Randomized, double-blind,
placebo-controlled, 12-week
treatment, 12-week follow-up,
multicenter clinical trial
Dose
Varenicline 1 mg BID
with an initial dose
titration for 12 weeks
Placebo
Varenicline 0.25 mg BID
Varenicline 0.5 mg BID
Varenicline 1.0 mg BID
with an initial dose
titration for 12 weeks
Placebo
Subjects
Cigarette smokers aged
21-73 years, smoked
~10 cigarettesjd, had
<3 months of smoking
abstinence in the past
year, motivated to quit
Cigarette smokers aged
18-75 years, smoked
~10 cigarettesjd
during the previous
year, without a period
of smoking abstinence
>3 months
Objectives
Primary end point:
exhaled CO-confirmed
CAR during the last
4 weeks
Secondary end points:
(1) CAR from weeks 9-24;
(2) 7-day point prevalence
abstinence rates at
weeks 12-24
Primary end point:
exhaled CO-confirmed
4-week CAR for weeks
9-12
Secondary end point:
CAR weeks 9-24 and
weeks 9-52
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Aubin et al40 52-Week, Phase III, open-label, Varenicline 1 mg BID with
randomized, multicenter trial an initial dose titration
for 12 weeks
NRT from target quit date
21 mgjd for 6 weeks,
14 mgjd for 2 weeks,
then 7 mgjd for 2 weeks
Cigarette smokers aged
18-75 years, weight
>45.5 kg, body mass
index 15-38 kgjm 2 ,
smoked ~15 cigarettesjd,
had <3 months of
smoking abstinence in
the past year, motivated
to quit
Primary end point:
self-reported and
exhaled CO-confirmed
4-week CAR for weeks
9-12 (varenicline) and
weeks 8-11 weeks (NRT)
Secondary end points:
(1) CO-confirmed CAR
for the last 4 weeks of
treatment through
weeks 24-52 (vareni-
cline, weeks 9-24 and
9-52; NRT, weeks
8-24 and 8-52); (2) 7-day
point prevalence
abstinence rates at
weeks 24 and 52
SR = sustained release; CO = carbon monoxide; CAR = continuous abstinence rate; CQR = continuous quit rate; MNWS = Minnesota Nicotine With-
drawal Scale; mCEQ = Modified Cigarette Evaluation Questionnaire; NRT = nicotine replacement therapy.
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urge-to-smoke item of the Minnesota Nicotine Withdrawal Scale (MNWS)41 and the
10-item Brief Questionnaire of Smoking Urges (QSU-brief).42 The Modified Ciga-
rette Evaluation Questionnaire (mCEQ) was used to assess the reenforcing effects of
smoking. 43 Randomized subjects received 1 of 3 varenicline tartrate dose regimens
(0.3 mg QD [n = 126; male, 50.0%; white, 88.1%; mean (SD) age, 41.9 (10.6) years},
1 mg QD [n = 126; male, 43.7%; white, 88.1%; mean (SD) age, 42.9 (10.5) years},
or 1 mg BID [n = 125; male, 50A%; white, 85.6%; mean (SD) age, 41.9 (9.8) years}
for 6 weeks plus placebo for 1 week), bupropion hydrochloride SR 150 mg BID (n =
126; male, 45.2%; white, 83.3%; mean [SD} age, 40.5 [l0.8} years) for 7 weeks, or
matched placebo (n = 123; male, 52.0%; white, 87.8%; mean [SD} age, 41.6 [lOA} years)
for 7 weeks. All subjects administered their study medication for 1 week before at-
tempting to quit smoking on day 8 of the study.35 The 4-week CQRs were signifi-
cantly higher for varenicline tartrate 1 mg BID (48.0%; P < 0.001) and 1 mg QD
(37.3%; P < 0.001) versus placebo (17.1 %) and for bupropion SR (33.3%; P = 0.002)
versus placebo. The CO-confirmed CQR from week 4 to weeks 12,24, and 52 for the
varenicline tartrate 1-mg BID group were significantly higher than that for the pla-
cebo group at each time point. The CQR rate for bupropion SR was significantly
higher than that for placebo only at week 12. Craving, as assessed using both the
MNWS urge-to-smoke item and the QSU-brief total score, was reduced significantly
with varenicline tartrate 1 mg BID compared with placebo at all weekly time points.
Bupropion SR reduced craving compared with placebo, although the differences
reached statistical significance at week 5 and 7 using the 2 instruments. Discontinu-
ation due to treatment-emergent adverse events (AEs) was 15.9% with bupropion SR,
11.2% to 14.3% with varenicline, and 9.8% with placebo. No dose-related increases
occurred in relation to AEs with varenicline (Table II).
In another Phase II multicenter trial, the efficacy and tolerability of 4 varenicline
dose regimens-2 with progressive dosing during the first week (titrated) and 2 with
a fixed dosing schedule (nontitrated)-were studied. 32 The study was carried out in
2 phases: a 12-week, randomized, double-blind, placebo-controlled study with weekly
visits followed by a 40-week assessment after discontinuation of the regimen. The
subjects included healthy individuals (aged 18-65 years) who smoked ;;,10 cigarettes
per day. Subjects were randomly assigned to receive varenicline 0.5 mg BID nonti-
trated (n = 129; male, 45.0%; white, 85.3%; mean [SD} age, 42.9 [l0.l} years),
varenicline 0.5 mg BID titrated (n = 130; male, 53.1%; white, 80.8%; mean [SD}
age, 43.5 [l0.5} years), varenicline 1.0 mg BID nontitrated (n = 129; male, 48.8%;
white, 83.7%; mean [SD} age, 43.7 [l0.0} years), varenicline 1.0 mg BID titrated
(n = 130; male, 48.5%; white, 80.8%; mean [SD} age, 42.2 [l0.7} years), or placebo
(n = 129; male, 51.9%; white, 72.1%; mean [SD} age, 43.0 [9A} years) for 12 weeks.
Long-term efficacy was assessed during a 40-week follow-up period. The primary ef-
ficacy measures were the CO-confirmed 4-week CQR for weeks 4 through 7 and 9
through 12 during treatment and the continuous abstinence rate (CAR) for weeks 9
through 52 for each dose relative to placebo. Secondary efficacy end points during the
treatment period included the CO-confirmed 7-day point prevalence abstinence
(PPA) (ie, abstaining from smoking during the preceding 7 days) and changes in the
45
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MNWS and the mCEQ by treatment group. The 4-week CQR for weeks 4 through
7 and 9 through 12 were significantly greater in the varenicline treatment groups
compared with the placebo group. The CQRs for weeks 4 through 7 were signifi-
cantly higher for the varenicline 0.5-mg BID nontitrated and titrated groups (37.2%
and 35.4%, respectively; both, P < 0.001) and for the varenicline 1.0-mg BID nonti-
trated and titrated groups (38.8% and 40.8%; both, P < 0.001) compared with pla-
cebo (10.9%). During weeks 9 through 12, CQRs were significantly higher for the
varenicline 0.5-mg BID nontitrated and titrated groups (47.3% and 40.8%, respec-
tively; both, P < 0.001) and for the varenicline 1.0-mg BID nontitrated and titrated
groups (44.2% and 54.6%; both, P < 0.001) compared with placebo (11.6%). At
week 12, 20.8% to 24.0% of subjects in the varenicline groups were continuously
abstinent compared with 7.0% in the placebo group. At weeks 24 and 52, the rates
decreased to approximately one third to one half of the rates observed at week 12 but
remained significantly higher for the varenicline groups versus placebo32 (Table II).
In a Phase III, randomized, double-blind, placebo- and active-treatment controlled,
parallel-group, multicenter clinical trial, 1025 healthy individuals who smoked were en-
rolled for a treatment phase of 12 weeks with a 40-week nondrug follow-up period.36
Participants received the titrated active drugs as either varenicline 1 mg BID (n = 352;
male, 50.0%; white, 79.5%; mean [SD} age, 42.5 [l1.l} years), bupropion SR
150 mg BID (n = 329; male, 58.4%; white, 80.2%; mean [SD} age, 42.0 [l1.7} years)
or placebo (n = 344; male, 54.1%; white, 76.2%; mean [SD} age, 42.6 [l1.8} years)
through week 12.36 The primary end point was exhaled CO-confirmed 4-week CAR
for weeks 9 through 12 (defined as the proportion of participants who reported no
smoking [not even a puff] or use of any nicotine-containing products, confirmed by
an exhaled CO measurement of <;10 ppm). The secondary end points were CAR from
weeks 9 through 24 and from weeks 9 through 52. Other secondary end points were
7-day PPA rates at weeks 12,24, and 52. The MNWS, QSU-brief, and mCEQ were
used to assess the outcomes related to craving, withdrawal, and the reinforcing effects
of smoking. The hierarchy of comparisons was varenicline versus placebo followed by
varenicline versus bupropion SR. The CO-confirmed 4-week CAR for weeks 9
through 12 was significantly higher for varenicline versus placebo (44.0% vs 17.7%;
P < 0.001) and versus bupropion SR (29.5%; P < 0.001). Bupropion SR was also
significantly higher compared with placebo (17.7%; P < 0.001). The CAR for weeks
9 through 24 was significantly higher for varenicline versus placebo (29.5% vs 10.5%;
P < 0.001) and versus bupropion SR (20.7%; P = 0.007). The CAR for weeks 9
through 52 was significantly greater for varenicline than for placebo (21.9% vs 8.4%;
P < 0.001), but the difference was not significant as compared with bupropion SR
(16.1%). The 7-day PPA at week 12 was significantly higher for varenicline versus
placebo (50.3% vs 21.2%; P < 0.001) and versus bupropion SR (35.9%; P < 0.001).
At week 24, 33.5% of the varenicline group were abstinent versus 14.5% of the pla-
cebo group (P < 0.001) and 24.9% of the bupropion SR group (P = 0.01). At week 52,
the 7-day PPA rate was 28.1% in the varenicline group versus 14.0% in the placebo
group (P < 0.001) and 22.8% in the bupropion SR group (P = 0.13). Both varenicline
and bupropion SR were associated with a significant reduction in the urge to smoke
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and negative effects compared with placebo (both, P < 0.001). The 52-week study
completion rates were 60.5% for varenicline, 56.0% for bupropion SR, and 54.0% for
placebo. Participants who withdrew prematurely from the study were assumed to have not
been able to quit smoking. The most common reason for discontinuation for both treat-
ment and nondrug follow-up was loss to follow-up (Table II and III).
A Phase III, randomized, double-blind, placebo-controlled, multicenter trial was
conducted to determine the efficacy and tolerability of varenicline for smoking cessa-
tion compared with placebo or bupropion SR.4 The study consisted of a 12-week
treatment period with follow-up to 52 weeks. A total of 1027 participants were ran-
domly assigned to varenicline titrated to 1 mg BID, bupropion SR titrated to 150 mg
BID, or placebo for 12 weeks, plus weekly smoking cessation counseling. The primary
end point was the 4-week CAR for the last 4 weeks of study drug treatment (weeks 9-
12). CARs from weeks 9 through 24 and weeks 9 through 52 were evaluated as sec-
ondary end points. Statistical significance was declared within each end point by
comparing varenicline with placebo and varenicline with bupropion SR. During the
last 4 weeks of treatment (weeks 9-12),43.9% of participants in the varenicline group
were continuously abstinent from smoking compared with 17.6% in the placebo
group (P < 0.00l) and 29.8% in the bupropion SR group (P < 0.00l). For weeks 9
through 24, 29.7% of participants in the varenicline group were continuously absti-
nent compared with 13.2% in the placebo group (P < 0.00l) and 20.2% in the bu-
propion SR group (P = 0.003). For weeks 9 through 52, 23.0% of participants in the
varenicline group were continuously abstinent compared with 10.3% in the placebo
group (P < 0.00l) and 14.6% in the bupropion SR group (P = 0.004). The odds ratio
Table III. Results of varenicline clinical trials.
Primary End Point
Secondary End Points
Trial (CAR weeks 9-12) CAR weeks 9-24 CAR weeks 9-52
Jorenby et al4 Varenicline 43.9% Varenicline 29.7% Varenicline 23.0%
Bupropion SR 29.8% Bupropion SR 20.2% Bupropion SR 14.6%
Placebo 17.6% Placebo 13.2% Placebo 10.3%
Gonzales et al36 Varenicline 44.0% Varenicline 29.5% Varenicline 21.9%
Bupropion SR 29.5% Bupropion SR 20.7% Bupropion SR 16.1%
Placebo 17.7% Placebo 10.5% Placebo 8.4%
Tonstad et a1 37* Varenicline 49.6% Varenicline 43.6%
Placebo 36.9% Placebo 36.9%
Tsai et al38 Varenicline 32.3% Varenicline 46.8%
Placebo 70.5% Placebo 21.8%
Aubin et al40 Varenicline 55.9% Varenicline 32.4% Varenicline 26.1%
NRT 43.2% NRT 27.3% NRT 20.3%
CAR = continuous abstinence rate; SR = sustained release; NRT = nicotine replacement therapy.
*Primary end point = CAR weeks 13-24; secondary end point = CAR weeks 13-52.
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comparing bupropion SR with placebo at the end of the study was not statistically
significant. During weeks 1 through 7, subjects in the varenicline group reported
significantly less urge to smoke (P < 0.00l) and had significantly fewer AEs (P =
0.00l) than those in the placebo group, as assessed using the MNWS. Bupropion SR
was associated with comparable relief from the urge to smoke and tolerability profile
(compared with placebo) but was associated with significantly increased ratings of
insomnia (P < 0.00l). In the varenicline, bupropion SR, and placebo groups, 10.5%,
12.6%, and 7.3%, respectively, of participants discontinued the treatment due to AEs.
Overall study completion rates at week 52 were 70% in the varenicline group, 65%
in the bupropion SR group, and 60% in the placebo group. At week 52, only those
who met all criteria were classified as abstinent (Tables II and III).
A 52-week multicenter trial was conducted to determine whether subjects who
quit smoking after 12 weeks of treatment with varenicline maintained greater absti-
nence rates than placebo controls during an additional 12 weeks of treatment and
until 52 weeks after treatment initiationY During the first 12 weeks of open-label
treatment, subjects were given varenicline 1 mg BID (n = 1927; male, 48.8%; white,
96.2%; mean [SD} age, 44.2 [l0.7} years). Then the patients who had successfully
abstained from smoking and other uses of tobacco and NRT for at least the last
7 days of the treatment period were randomly assigned to receive either varenicline
1 mg BID (n = 603; male, 50.2%; white, 96.7%; mean [SD} age, 45A [lOA} years)
or placebo (n = 607; male, 48.3%; white, 97.0%; mean [SD} age, 45.3 [lOA} years)
and continued into a 12-week, double-blind treatment phase. Thereafter, the subjects
continued into a nontreatment follow-up phase for an additional 28 weeks (for a total
of 52 weeks in the study). The primary efficacy end point was CO-confirmed CAR
from weeks 13 through 24. The secondary efficacy end points were the CAR from
weeks 13 through 52. The MNWS was used to assess the experience of craving and
withdrawal after the end of treatment with varenicline. During the last week (week
12) of treatment, 64.1 % of the subjects who had been cigarette smokers were absti-
nent from smoking, other uses of tobacco, or use of NRT. The CAR for weeks 13
through 24 was significantly higher for subjects randomized to varenicline than to
placebo (70.5% vs 49.6%; P < 0.00l). The CAR for weeks 13 through 52 was also
significantly higher for the varenicline group than for the placebo group (43.6% vs
36.9%; P = 0.02). The 7-day point prevalence of abstinence at week 24 (P < 0.00l)
and at week 52 (P = 0.0l) was significantly higher for subjects who received vareni-
cline than for those who received placebo. The median time to the first lapse/smoke
(postrandomization to double-blind treatment) was significantly longer for subjects re-
ceiving varenicline than for those receiving placebo (198 vs 87 days, respectively; log-
rank P < 0.00l). During the open-label phase, 11.9% experienced AEs that led to
treatment discontinuation. During the double-blind treatment phase, the incidence
of AEs was similar for the varenicline and placebo groups (46% and 45%, respec-
tively). In this randomized clinical trial, smokers who successfully quit after taking
open-label varenicline for an initial 12 weeks experienced a significantly re-
duced relapse rate when taking an additional 12 weeks of varenicline 1 mg BID com-
pared with placebo (Tables II and III).
48
K. KAUR ET AL.
The results of 2 randomized, double-blind, placebo-controlled trials conducted in
an Asian population were consistent with the results observed in the Phase III trials.
In a randomized, double-blind, placebo-controlled trial in Korea and Taiwan with a
12-week treatment period and a 12-week follow-up period, subjects were adminis-
tered varenicline 1 mg BID (titrated during the first week) (n = 126; male, 84.9%;
mean age, 39.7 years) and placebo (n = 124; male, 92.7%; mean age, 40.9 years).
The smoking cessation rates were significantly higher in the varenicline group than
in the placebo group at the end of treatment (59.5% vs 32.3%; P < 0.001). Posttreat-
ment CAR (weeks 9-24) was significantly greater in the varenicline group than the
placebo group (46.8% vs 21.8%; P < 0.001). The 7-day PPA was 67.5% with vareni-
cline versus 36.3% with placebo at week 12 and 57.1% versus 29.0% with placebo at
week 24 (both, P < 0.001).38 Nakamura et a13 9 conducted a randomized, double-blind,
placebo-controlled, multicenter, parallel-group study in which the subjects (n = 515;
male, 74.8%; mean age range, 39.0--40.2 years) were randomized to receive vareni-
cline 0.25 mg BID, 0.5 mg BID, 1.0 mg BID, or placebo for 12 weeks followed by a
40-week nontreatment follow-up phase. The CAR achieved with varenicline 1 mg
BID was 65.4% (highest among all doses) compared with 39.5 % with placebo (P <
0.001). The CAR for weeks 9 through 52 was significantly greater for varenicline
1 mg BID than placebo (34.6% vs 23.3%; P = 0.036). The CARs for weeks 9 through
24 of treatment with varenicline 0.25, 0.5, and 1.0 mg BID were 33.6%,35.2%, and
37.7%, respectively, while the CARs for weeks 9 through 52 at 0.25 and 0.5 mg BID
were 27.3% and 28.9% but failed to reach significance versus placebo (29.5% for
weeks 9-24 and 23.3% for weeks 9-52) (Tables II and III).
Varenicline was compared to transdermal NRT in a Phase III, randomized, open-
label, multicenter tria1. 4o Participants were aged 18 to 75 years and smoked at least
15 cigarettes per day with a period of abstinence < 3 months in the previous year.
Participants were randomly allocated to receive either titrated varenicline 1 mg BID
(n = 376; male, 48.4%; white, 92.6%; mean [SD} age, 42.9 [l0.5} years) for 12 weeks
or NRT transdermal patches (n = 370; male, 50.0%; white, 93.5%; mean [SD} age,
42.9 [l2.0} years) for 10 weeks. The primary end point was CO-confirmed CAR dur-
ing the last 4 weeks of treatment (varenicline, weeks 9-12; NRT, weeks 8-11). Sec-
ondary efficacy end points included CO-confirmed CAR for the last 4 weeks of treat-
ment for weeks 24 through 52. The CAR for the last 4 weeks of treatment was
significantly greater for varenicline than for NRT (55.9% vs 43.2%; P < 0.001). The
CARs for weeks 24 through 52 were not significantly higher for varenicline than
NRT. For weeks 1 through 7, the scores on the urge-to-smoke scale were significantly
lower with varenicline than with NRT (P < 0.001). With varenicline, participants
reported significantly lower smoking satisfaction (P < 0.001), psychological reward
(P = 0.001), and craving reduction (P < 0.001) (Tables II and III).
VARENICLINE SAFETY PROFILE AND TOLERABILITY
The safety profile of varenicline was reported in 6 clinical trials.4,36-40 Gonzales et a136
reported study drug discontinuations due to AEs were 8.6% for varenicline, 15.2%
for bupropion SR, and 9.0% for placebo. Nausea, the most common AE with vareni-
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cline (28.1%), was mostly mild to moderate, diminished over time, and resulted in
few treatment discontinuations (2.6%). Insomnia was the most common AE with
bupropion SR (21.9%). ]orenby et al4 reported that nausea was the most common AE
with varenicline (29.4%). Other common symptoms in the varenicline group were
insomnia (14.3%) and abnormal dreams (13.1 %). Insomnia was the most common AE
associated with bupropion SR (21.2%), followed by headache (7.9%) and dry mouth
(7.6%). Tonstad et a137 reported that the AEs that contributed most frequently to
treatment discontinuation were nausea (3.2%), headache (1.0%), insomnia (0.9%),
depression (0.8%), and fatigue (0.6%). Vomiting was reported in 2.9% of subjects.
Tsai et a13s reported that nausea (varenicline 43.7% and placebo 11.3%), insomnia
05.1% and 13.7%, respectively), increased appetite (7.9% and 6.5%), constipation
(7.1% and 6.5%), anxiety (5.6% and 2.4%), and abnormal dreams (5.6% and 0.8%)
were the most common AEs. Nakamura et a13 9 reported that the most prevalent AEs
with varenicline 1 mg BID were nasopharyngitis (35.9%), nausea (24.4%), and head-
ache 00.3%). Nausea was dose related (7.2% at 0.25 mg BID, 9.7% at 0.5 mg BID,
and 24.4% at 1 mg BID) versus placebo (7.8%). Aubin et al40 reported that the most
frequent AEs in both treatment groups were nausea (varenicline group 37.2%, NRT
group 9.7%), insomnia (21.3% and 19.2%, respectively), headache 09.1% and
9.7%), and abnormal dreams (11.7% and 8.4%).
The most commonly reported AEs were gastrointestinal disorders (nausea [usually
mild to moderate and transient}, vomiting, flatulence, constipation, dyspepsia, and
abdominal pain), psychiatric disorders (insomnia, abnormal dreams, and irritability),
headache, nasopharyngitis, and fatigue.4,36,4o Postmarketing surveillance raised fur-
ther tolerability issues. The US Food and Drug Administration (FDA) issued a public
health advisory reporting an association between varenicline and an increased risk of
behavioral change, agitation, depressed mood, and suicidal ideation and behavior.44
The safety profile review of varenicline by the FDA is ongoing.
Use in Pregnant Women
In preclinical trials, oral administration ofvarenicline succinate 30 mg/kg . d-1 to preg-
nant rabbits was associated with reduced fetal weight; this reduction was not evident
at 10 mg/kg . d-1. In an experimental rat study, varenicline succinate 15 mg/kg . d-1
orally was associated with decreased fertility and increased auditory startle response in
the offspring.s There are no adequate, well-controlled studies in pregnant women, so
varenicline cannot be recommended for smoking cessation during pregnancy.45
DISCUSSION
With its unique mechanism of action, varenicline may be an asset in the smoking
cessation armamentarium. In Phase III trials,4,36 the CARs for weeks 9 through
52 were significantly higher with varenicline than with placebo. All the clinical trials
reviewed for this study reported significantly better results with varenicline than with
placebo with regard to the MNWS, QSU-brief, and mCEQ scales. Varenicline was
also more efficacious than bupropion SR through 24 weeks. Extended use of vareni-
cline helps recent ex-smokers maintain their abstinence and prevents relapse. 37 How-
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ever, the results of certain trials4,36 have also raised several issues. In the Phase III
trials, generally healthy smokers were included, which may not represent the smokers
who are most likely to seek treatment. 36 Patients with serious medical illness or cur-
rent or recent depression were excluded from the tria1.4 It is not clear whether vareni-
cline can help maintain abstinence beyond 52 weeks, especially since it had a rela-
tively small margin of improvement over placebo (43.6% vs 36.9% abstinent at
52 weeks)Y The trials involved more intensive in-person and telephone counseling
than could be done in the community and in general practice.
The studies did not address the effects of varenicline on smokers with a history of
bupropion use. Some smokers might have taken bupropion for smoking cessation or
for treatment of depression; therefore, the results might be different in the broader
population. The CAR at week 52 for those assigned to receive bupropion SR was
somewhat lower36 than that reported in prior bupropion SR studies reporting 52-week
CAR (CAR from week 4 through 7 was 46% and at 12 months was 21%).8,46 It is
important to note the 43.6% CAR achieved at week 52 in the study by Tonstad et
a137 reflected only participants who were abstinent for ::0-1 week at the end of the first
12 weeks of treatment. There was a significant difference in validated CAR rates at
the end of treatment and a smaller but still significant difference 6 months laterY
The 12-week point prevalence rate of abstinence was unusually high (64.1 %) and
surpassed the rates of ~50% that were observed in the other 2 smoking cessation stud-
ies of 12 weeks of treatment with varenicline versus bupropion or placebo.4,36 This
difference might be due to the open-label design of the first phase of this study com-
pared with the double-blind design of the other studies. As of the writing of this
manuscript, there were no data regarding the efficacy of the combination of vareni-
cline and NRT. In addition, postmarketing surveillance is needed to detect any rare
but serious complications. While awaiting the answers to these questions, a prudent
course would be to view varenicline as a valuable addition to the pharmacotherapy
available to help individuals who smoke achieve smoking cessation. Varenicline might
prove to be particularly appropriate for those in whom other treatments have failed.
Appropriate use of varenicline may decrease the incidence of smoking, which is the
leading preventable risk to human health. Community-based trials of varenicline are
needed to test its efficacy and safety in individuals who smoke with varying comor-
bidities and risk patterns.
CONCLUSIONS
Varenicline is the first smoking cessation treatment that was associated with a sig-
nificant long-term relapse prevention effect (up to 52 weeks). Varenicline, with its
unique profile of agonist and antagonist properties, increased smoking cessation rates
(both short and long term) compared with both placebo and bupropion SR.
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